Moreover, accumulating evidence suggested PRGs as prognosis biomarkers for some types of cancers, including ovarian cancer and lung adenocarcinoma (Wei et al., 2020; Ye et al., 2021). This evidence concerns the gene GART and ovarian carcinoma.